A phase II study of [90Y]yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 2, 1999, Pages 99-111

  Kahn, Daniel ^a   Austin, J Christopher ^b   Maguire, Robert T ^b   Miller, Sara J ^b   Gerstbrein, Jack ^b   Williams, Richard D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antibody, monoclonal; Prostate specific membrane antigen; Radioimmunotherapy

Indexed keywords

CAPROMAB PENDETIDE IN 111; EDETATE CALCIUM DISODIUM; INDIUM; PROSTATE SPECIFIC ANTIGEN; YTTRIUM 90;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CONJUGATION; HUMAN; LEUKOPENIA; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; THROMBOCYTOPENIA;

EID: 0032964462     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.99     Document Type: Article

References (29)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6.
2. Lu-Yao GL, Friedman M, Yao S. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol 1997;157:2219.
3. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate specific antigen after anatomical radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24:395.
4. Kupelian PA, Kuthcher J, Levin HS, Klein EA. State T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37:1043.
5. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomic radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837.
6. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, et al. Radioimmunoscintigraphy with In 111-labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490.
7. Rodwell JD, Alvarez VL, Lee C, Lopes AD, Goers JW, Kind HD, et al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986;83:2632.
8. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227.
9. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone-refractory prostate cancer with Y-90-CYT-356 monoclonal antibody. Clin Cancer Res 1996;2:1287.
10. Patel A, Dorey F, Franklin J, DeKemion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific doubling time and log slope prostate specific antigen. J Urol 1998; 58:1441.
11. Barren RJ, Holmes EH, Boynton AL, Misrock SL, Murphy GP. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 1997; 30:65.
12. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30:232.
13. Diem K, Lentner C. Geigy Scientific Tables. Ardley, NY: Geigy Pharmaceuticals, 1986, p. 85.
14. Takayama TK, Lange PH. Radiation therapy for local recurrence of prostate cancer after radical prostatectomy. Urol Clin North Am 1994; 21:687.
15. Lange PH, Lightner DJ, Medini E, Reddy PK, Vassells RL. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 1990; 144:927.
16. Link P, Freiha FS, Stamey TA. Adjuvant therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 1991;145:532.
17. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713.
18. Klein EA. Management of elevated PSA after radical prostatectomy. J Urol 1993;149:349A.
19. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen following radical prostatectomy: early versus delayed treatment. J Urol 1994; 151:1575.
20. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994;69:613.
21. Wu JJ, King SC, Montana GS, McKinstry CA, Auscher MS. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostatespecific antigen. Int J Radiat Oncol Biol Phys 1995; 32:317.
22. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;158:173.
23. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111 indium-labeled monoclonal antibody CYT-356. J Urol 1994;152:1952.
24. Kahn D, Williams RD, Manyak MJ. In-111-Capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer following radical prostatectomy. J Urol 1998; 159:2041.
25. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902.
26. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927.
27. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific-membrane-antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30:232.
28. Stewart JSW, Hird V, Snook D, et al. Intraperitoneally yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8:1941.
29. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57:3629.